The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

What’s going on with Weight Watchers? With the CEO stepping down, a new body-positive approach, continual app changes, ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.